Over the years, Ellex has evolved from a small scientific laser company to a global leader in ophthalmic laser technology. Our steady expansion includes local sales and service support offices in North America, Japan, Europe and Australia and a network of distribution partners in more than 100 countries.
6 July 2017
Highlights: Total group unaudited sales of $71.7 million ($73.6 million in constant currency) for FY17, including strong iTrack™ sales growth to 30 June 2017 of $8.2 million ($8.5 million in constant currency) iTrack™ sales growth of 53% in Q4 FY17 in the USA, compared with same period in the prior year; 41% growth in unit sales for FY17 Laser and ultrasound sales $64.4 million in constant currency representing a CAGR of 8% over the last five years Ellex to increase funding in FY18 for major expansion of Ellex iTrack™ business unit Growth in FY18 will be underpinned by Ellex’s unique leading global position in non-pharmaceutical treatment of glaucoma Adelaide, Australia, 6 July, 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today provided a trading update on sales for the full year ended 30 June 2017 for its Ellex iTrack™ and laser and ultrasound business segments. Recap on Strategy Ellex is a globally
22 June 2017
Highlights: Ellex continues commitment to expanding global distribution network of Ellex iTrack™ business Accelerated recruitment and expansion of US-based sales team driving significant month-on-month sales growth Adelaide, Australia, 22 June 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, is pleased to provide the following update on recent sales and marketing activities for the Ellex iTrack™ business segment. Ellex iTrack™ is Ellex’s wholly owned, San Francisco Bay Area-based, subsidiary which specialises in the treatment of glaucoma using its iTrack™ patented microcatheter. Ellex is now experiencing significant month-on-month improvements in sales growth, attributed to the continued investment in sales and marketing, particularly within the US market and across other specifically targeted global markets during the financial year. Ellex iTrack™ US Sales Team Recruitment and Expansion Ellex iTrack™ has
6 June 2017
Highlight: Chinese government confirms regulatory approval for iTrack™ until 23 May 2022 – the only MIGS device to treat glaucoma approved in this market Adelaide, Australia, 6 June 2017– Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced an extension of regulatory approval in China for its minimally invasive glaucoma surgery (MIGS) device, Ellex iTrack™. On 2 June 2017, Ellex received advice from the Chinese government that the Ellex iTrack™ device’s approval for sale in China has been extended until 23 May 2022. Ellex iTrack™ is the only MIGS device approved for sale in China. China is a key market segment for Ellex iTrack™ and the Company is working with its distributor to train doctors in the iTrack™ surgery technique and build sales in the country. ABOUT ELLEX Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficient
Annual Report 2016
View Share Price
Note: Prices are delayed by at least 20 minutes and are sourced from the Australian Stock Exchange. Retrieving price information indicates your acceptance of the conditions.